Granulocytapheresis in inflamatory bowel disease: Efficacy of an induction plus maintenance sessions protocol at 32 weeks;Granulocitoaféresis en la enfermedad inflamatoria intestinal. Eficacia a 32 semanas con protocolo de inducción y sesiones de mantenimiento

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 11, 2007, Pages 628-635

  Fernández Pérez, Francisco José ^a   Rodriguez F ^a   De Sola, C ^a   Fernandez Moreno N ^a   Mendez I ^a   Vera, F ^a   Rivera, R ^a   Sanchez Cantos A ^a  

^a HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Crohn's disease; Granulocytoapheresis; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE; TACROLIMUS;

ADULT; AGED; APHERESIS; ARTICLE; CROHN DISEASE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOLLOW UP; GRANULOCYTAPHERESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; REMISSION; RETROSPECTIVE STUDY; SYNCOPE; THROMBOPHLEBITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CLINICAL PROTOCOLS; FEMALE; GRANULOCYTES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 40949158367     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Mahida YR. The key roleof macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000: 6; 21-33.
2. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subset in inflammatory bowel disease: Apparent recruitment from peripheral blood monocytes. Gut 1994; 35: 669-74.
3. Nikolaus S, Bauditz J, Gionchetti P, et al. Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998; 42: 470-6.
4. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51: 289-98.
5. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences. Gastroenterology 2004; 126: 1504-17.
6. Hanauer SB. Inflammatory bowel disease: Pathogenesis and theraputic opportunities. Inflamm Bowel Dis 2006: S3-S9.
7. Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 319-34.
8. Yamaji K, Tsuda H, Hashimoto H. Current topics on cytapheresis technologies. Ther Apher 2001; 5: 287-92.
9. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: S15-S21.
10. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte apheresis versus prednisolone in patients with active ulcerative colitis: A multicenter study. J Clin Apheesis 2001; 16: 1-9.
11. Doménech E, Hinojosa J, Esteve-Comas M, et al. Granulocytoapheresis in steroid-dependent inflammatory bowel disease: A prospective, open, pilot study. Aliment Pharmacol Ther 2004; 20: 1347-52.
12. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyteadsrptive apheresis for the treatment of active ulcerative colitis: A prospective uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003; 1: 28-35.
13. Yamamoto T, Umegae S, Kitagawa T, et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis. A prospective pilot study. Aliment Pharmacol Ther 2004; 20: 783-92.
14. Suzuki Y, Yoshimura N, Saniabadi AR, et al. Selective granulocyte and monocyte adsorptive apheresis as first-line treatment for steroid naïve patients with active ulcerative colitis: A prospective uncontrolled study. Dig Dis Sci 2004; 49: 565-71.
15. Ljung T, Thomsen O, Vatn M, et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007; 42: 221-7.
16. Cuenca F, García PJ, Mendoza JL, et al. Experiencia con la granulocitoaféresis en la enfermedad de Crohn. Rev Esp Enferm Dig 2004; 96: 501-6.
17. Matsui T, Nitshimute T, Mateke H, et al. Granulocytapheresis for Crohn's disease: A report on seven refractory patients. Am J Gastroenterol 2003; 98: 511-2.
18. Nagase K, Sawada K, Ohnishi K, et al. Complications of leukocytapheresis. Ther Apher 1998; 2: 120-4.
19. Cabriada JL, Doménech E, Gomollón F, et al. Documento de consenso en el uso de la granulocitoaféresis en pacientes con enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2006; 29 (2): 85-92.